Investorideas.com

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Biotech Could Launch Trial of Polyp Screening Test in March
January 19, 2022 (Investorideas.com Newswire) The start of the C-Scan study would be a major milestone for Check-Cap

Derm Biopharma Named Top Growth Pick For 2022
January 19, 2022 (Investorideas.com Newswire) Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024

This Pharmaceutical Company Has a Brilliant Concept
January 18, 2022 (Investorideas.com Newswire) Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs.

Medical Tech Stock News: ScreenPro (CSE: SCRN) Announces Expansion of Mobile COVID-19 Testing Units Division
Toronto, Ontario - January 14, 2022 (Newsfile Corp.) (Investorideas.com Newswire) ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that the Company is expanding newly deployed mobile testing units in Greater Vancouver and Greater Toronto Area.

Ph1 Trial Results of Dementia Drug Positive
January 13, 2022 (Investorideas.com Newswire) Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints

Biotech Co. Partners With Life Sciences Firms
January 12, 2022 (Investorideas.com Newswire) 2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed

Enrollment Done for COVID-19 Drug Trial
January 11, 2022 (Investorideas.com Newswire) Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway

2022 to be Catalyst Rich for Biopharma
January 11, 2022 (Investorideas.com Newswire) The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
MAINZ, Germany and LONDON, United Kingdom - January 11, 2022 (Investorideas.com Newswire) BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd ("InstaDeep") today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2.

Co.'s samRNA Vaccines Protect Better Against COVID Variants
January 10, 2022 (Investorideas.com Newswire) Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Guest Posts - Ideas from Contributors

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Cybeats Joins OASIS Open; Congratulates Cybeats Advisor, Duncan Sparrell, on Winning OASIS Distinguished Contributor Award
Toronto, Ontario--(Newsfile Corp. - January 21, 2022) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company"), is pleased announce that Cybeats has joined OASIS Open[1], where individuals, organizations, and governments come together to solve some of the world's biggest technical challenges through the development of open code and open standards.The work of OASIS[2] is supported by organizations from around the world[3]. Its member roster includes the likes of IBM, EMQ, Adobe, Accenture, Hitachi,...

Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
Calgary, Alberta--(Newsfile Corp. - January 21, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a Global Master Services Agreement with My Next Health ("MNH"), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit.My Next Health Inc. ("MNH") is the world's leading patient-based AI-functional genomic medical analysis company. MNH...

MustGrow and Bayer sign Exclusive Agreement to Develop Sustainable Organic Biologicals in Europe, Asia Pacific, Middle East and Africa
Exclusive agreement with Bayer to evaluate MustGrow's technologies to determine commercial potential.Bayer has the option to acquire exclusive rights to MustGrow's technologies for preplant soil fumigation, bioherbicide applications and postharvest food preservation of potatoes including sprout inhibition in the regions of Europe, Asia Pacific, Middle East and Africa. Bayer will fund and drive all laboratory, field development, regulatory work and market development.Saskatoon, Saskatchewan--(Newsfile Corp. - January 21, 2022) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB:...

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that it has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program. As compensation, Octagon Media Corp. will receive a payment of US$60,000 as...

Therma Bright Provides Update on U.S. Clinical Performance Study
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that its U.S. Clinical Performance Study is still underway. Once the clinical data has been completed and tabulated, the final results will be reported to the marketplace and the U.S. Food & Drug Administration for...

Subscribe to Biotech News